ABSI
Absci Corporation
There isn't enough reported data to score ABSI yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ABSI Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
ABSI's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ABSI PE Valuation
ABSI has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ABSI Forward outlook
There aren't enough analyst estimates for ABSI to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ABSI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.78 | +$0.13 |
| Q2 2026 | -$0.79 | +$0.16 |
| Q1 2026 | -$0.82 | +$0.11 |
| Q4 2025 | -$0.84 | +$0.10 |
| Q3 2025 | -$0.91 | +$0.02 |
| Q2 2025 | -$0.95 | -$0.02 |
| Q1 2025 | -$0.93 | +$0.23 |
| Q4 2024 | -$0.94 | +$0.26 |
ABSI has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ABSI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $304K | -20% |
| Q2 2026 | $318K | -46% |
| Q1 2026 | $215K | -82% |
| Q4 2025 | $650K | -2.3% |
| Q3 2025 | $378K | -78% |
| Q2 2025 | $593K | -53% |
| Q1 2025 | $1.2M | +31% |
| Q4 2024 | $665K | +97% |
ABSI's revenue has slid since its 2023 peak: $304,000 last quarter, down 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -11511% | -3534 points |
| Q2 2026 | -10742% | -5448 points |
| Q1 2026 | -14347% | -11995 points |
| Q4 2025 | -4776% | -298 points |
| Q3 2025 | -7977% | -6279 points |
| Q2 2025 | -5294% | -3190 points |
| Q1 2025 | -2352% | +265 points |
| Q4 2024 | -4477% | +2842 points |
ABSI's operating margin was −11511% last quarter, down 3534 points from the same quarter a year ago, near the bottom of its range since 2020.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ABSI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ABSI on profitability, with a higher operating margin.
ABSI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$29.5M | -$3.5M |
| Q2 2026 | -$27.6M | -$10.5M |
| Q1 2026 | -$26.3M | -$4.5M |
| Q4 2025 | -$29.1M | -$12.1M |
| Q3 2025 | -$26M | -$5.2M |
| Q2 2025 | -$17.1M | +$80K |
| Q1 2025 | -$21.9M | -$4M |
| Q4 2024 | -$17M | -$2M |
ABSI has burned cash in almost every quarter: −$112M over the past year, against −$82M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ABSI on cash generation, producing positive trailing cash flow while its opponent burns cash.
ABSI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.1% | +14.3M shares |
| 1 year | +19% | +28M shares |
| 3 years | +86% | +79.6M shares |
| 5 years | +874% | +154M shares |
| Available history | +90% | +81.4M shares |
ABSI has 172M diluted shares, up 19% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ABSI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ABSI Net Leverage
ABSI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ABSI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.8 | Neutral |
| Stochastic | 52.6 | Neutral |
ABSI's weekly RSI is 53 (neutral) and its Stochastic is 53 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ABSI PE vs Healthcare Sector
ABSI has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ABSI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.85 | 7.3% below |
| 20 week MA | $9.39 | 2.8% below |
| 50 week MA | $6.24 | 46% above |
| 100 week MA | $4.70 | 94% above |
| 200 week MA | $3.87 | 136% above |
ABSI has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ABSI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $22.9 | $8.67 | -62% |
| 2022 | $8.67 | $2.17 | -75% |
| 2023 | $2.17 | $4.20 | +94% |
| 2024 | $4.20 | $2.77 | -34% |
| 2025 | $2.77 | $3.57 | +29% |
| 2026 YTD | $3.57 | $9.13 | +156% |
ABSI has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.